Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glycomimetics Inc (NQ: GLYC )

1.900 -0.020 (-1.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 185,941
Open 1.960
Bid (Size) 1.850 (15)
Ask (Size) 1.950 (6)
Prev. Close 1.920
Today's Range 1.850 - 1.980
52wk Range 0.5100 - 4.160
Shares Outstanding 64,245,674
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics: A Breakthrough In Hematopoietic Stem Cell Transplantation
Blood cancers such as AML, MM, and MDS affect a terrible toll on patients and their loved ones. Glycomimetics may be such a company that can offer patients suffering from various blood cancers hope... 
Via Talk Markets

Performance

YTD
-34.71%
-34.71%
1 Month
+34.75%
+34.75%
3 Month
+25.83%
+25.83%
6 Month
-11.21%
-11.21%
1 Year
+192.31%
+192.31%

More News

Read More
GlycoMimetics: Q1 Earnings Insights
Via Benzinga
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023
From GlycoMimetics, Inc.
Via Business Wire
Earnings Preview For GlycoMimetics
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023
From GlycoMimetics, Inc.
Via Business Wire
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
Via Benzinga
GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference
From GlycoMimetics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
$3M Bet On This Biotechnology Stock? Check Out These 3 Penny Stocks Insiders Are Buying
Via Benzinga
Pagaya Technologies To Rally Around Over 120%? Here Are 10 Other Analyst Forecasts For Thursday
Via Benzinga
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlycoMimetics, Inc.
Via Business Wire
Nasdaq Surges 90 Points; Credo Technology Group Shares Slide
Via Benzinga
Why Sabre Are Trading Lower By 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Gold Down 1%; Roblox Shares Spike Higher
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Dow Dips 200 Points; US Retail Sales Rise 3%
Via Benzinga
GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Audio Discussion And Analysis With Dan Cohen And Scott Matusow
Via Talk Markets
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From GlycoMimetics, Inc.
Via Business Wire
Top 5 Health Care Stocks That May Dip
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.